Literature DB >> 17325227

Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria.

Sunny Oyakhirome1, Saadou Issifou, Peter Pongratz, Fortune Barondi, Michael Ramharter, Jürgen F Kun, Michel A Missinou, Bertrand Lell, Peter G Kremsner.   

Abstract

Fosmidomycin-clindamycin therapy given every 12 h for 3 days was compared with a standard single oral dose of sulfadoxine-pyrimethamine. The two treatments showed comparably good tolerabilities and had an identical high degree of efficacy of 94% in a randomized trial carried out with 105 Gabonese children aged 3 to 14 years with uncomplicated malaria. These antimalarials merit further clinical exploration.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17325227      PMCID： PMC1855537          DOI： 10.1128/AAC.01448-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Antimalarial combinations.

Authors:  Peter Gottfried Kremsner; Sanjeev Krishna
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

2.  Treating malaria in Africa.

Authors:  Brian Greenwood
Journal:  BMJ       Date:  2004-03-06

3.  Pharmacokinetic studies of clindamycin hydrochloride in humans.

Authors:  R M DeHaan; C M Metzler; D Schellenberg; W D VandenBosch; E L Masson
Journal:  Int J Clin Pharmacol       Date:  1972-06

4.  New emerging Plasmodium falciparum genotypes in children during the transition phase from asymptomatic parasitemia to malaria.

Authors:  Jürgen F J Kun; Michel A Missinou; Bertrand Lell; Milena Sovric; Hanna Knoop; Birgit Bojowald; Oliver Dangelmaier; Peter G Kremsner
Journal:  Am J Trop Med Hyg       Date:  2002-06       Impact factor: 2.345

Review 5.  Fosmidomycin for the treatment of malaria.

Authors:  Jochen Wiesner; Steffen Borrmann; Hassan Jomaa
Journal:  Parasitol Res       Date:  2002-11-30       Impact factor: 2.289

6.  Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children.

Authors:  Steffen Borrmann; Ayola A Adegnika; Pierre-Blaise Matsiegui; Saadou Issifou; Andreas Schindler; Denise P Mawili-Mboumba; Thomas Baranek; Jochen Wiesner; Hassan Jomaa; Peter G Kremsner
Journal:  J Infect Dis       Date:  2004-02-16       Impact factor: 5.226

7.  Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria.

Authors:  Steffen Borrmann; Saadou Issifou; Gilbert Esser; Ayola A Adegnika; Michael Ramharter; Pierre-Blaise Matsiegui; Sunny Oyakhirome; Dénise P Mawili-Mboumba; Michel A Missinou; Jürgen F J Kun; Hassan Jomaa; Peter G Kremsner
Journal:  J Infect Dis       Date:  2004-09-21       Impact factor: 5.226

8.  Fosmidomycin, a novel chemotherapeutic agent for malaria.

Authors:  Bertrand Lell; Ronnatrai Ruangweerayut; Jochen Wiesner; Michel Anoumou Missinou; Andreas Schindler; Thomas Baranek; Martin Hintz; David Hutchinson; Hassan Jomaa; Peter Gottfried Kremsner
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

9.  Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial.

Authors:  A Alloueche; W Bailey; S Barton; J Bwika; P Chimpeni; C O Falade; F A Fehintola; J Horton; S Jaffar; T Kanyok; P G Kremsner; J G Kublin; T Lang; M A Missinou; C Mkandala; A M J Oduola; Z Premji; L Robertson; A Sowunmi; S A Ward; P A Winstanley
Journal:  Lancet       Date:  2004-06-05       Impact factor: 79.321

10.  In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin.

Authors:  Jochen Wiesner; Dajana Henschker; David B Hutchinson; Ewald Beck; Hassan Jomaa
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191
View more
  23 in total

1.  A chemical rescue screen identifies a Plasmodium falciparum apicoplast inhibitor targeting MEP isoprenoid precursor biosynthesis.

Authors:  Wesley Wu; Zachary Herrera; Danny Ebert; Katie Baska; Seok H Cho; Joseph L DeRisi; Ellen Yeh
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Tropical medicine at the University of Tübingen.

Authors:  Peter Gottfried Kremsner
Journal:  Wien Klin Wochenschr       Date:  2010-03       Impact factor: 1.704

3.  David Roos. Interview by H. Craig Mak.

Authors:  David Roos
Journal:  Nat Biotechnol       Date:  2011-02       Impact factor: 54.908

Review 4.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

5.  In vitro activity of antifungal drugs against Plasmodium falciparum field isolates.

Authors:  Peter Pongratz; Florian Kurth; Ghyslain Mombo Ngoma; Arti Basra; Michael Ramharter
Journal:  Wien Klin Wochenschr       Date:  2011-07-07       Impact factor: 1.704

6.  Inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies.

Authors:  Lisheng Deng; Jiasheng Diao; Pinhong Chen; Venugopal Pujari; Yuan Yao; Gang Cheng; Dean C Crick; B V Venkataram Prasad; Yongcheng Song
Journal:  J Med Chem       Date:  2011-06-02       Impact factor: 7.446

7.  Inadequate efficacy of a new formulation of fosmidomycin-clindamycin combination in Mozambican children less than three years old with uncomplicated Plasmodium falciparum malaria.

Authors:  Miguel Lanaspa; Cinta Moraleda; Sónia Machevo; Raquel González; Beatriz Serrano; Eusebio Macete; Pau Cisteró; Alfredo Mayor; David Hutchinson; Peter G Kremsner; Pedro Alonso; Clara Menéndez; Quique Bassat
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

8.  Determination of the active stereoisomer of the MEP pathway-targeting antimalarial agent MMV008138, and initial structure-activity studies.

Authors:  Zhong-Ke Yao; Priscilla M Krai; Emilio F Merino; Morgan E Simpson; Carla Slebodnick; Maria Belen Cassera; Paul R Carlier
Journal:  Bioorg Med Chem Lett       Date:  2015-02-21       Impact factor: 2.823

9.  Antimalarial and Structural Studies of Pyridine-containing Inhibitors of 1-Deoxyxylulose-5-phosphate Reductoisomerase.

Authors:  Jian Xue; Jiasheng Diao; Guobin Cai; Lisheng Deng; Baisong Zheng; Yuan Yao; Yongcheng Song
Journal:  ACS Med Chem Lett       Date:  2013-02-14       Impact factor: 4.345

10.  Expression, characterization and inhibition of Toxoplasma gondii 1-deoxy-D-xylulose-5-phosphate reductoisomerase.

Authors:  Guobin Cai; Lisheng Deng; Jian Xue; Silvia N J Moreno; Boris Striepen; Yongcheng Song
Journal:  Bioorg Med Chem Lett       Date:  2013-01-30       Impact factor: 2.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.